An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Conclude your understanding of lymphoma with an in-depth look at its signs and symptoms, from common indicators to subtle clues.

Speaker : Dr Suvir Singh

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

In this webinar, a detailed discussion is done on CROWN trial update: Optimizing 1st-line ALK+ mNSCLC management.

Speakers : Dr Jyoti Wadhwa ( Moderator ) ,Dr Atul Sharma ( Expert Panel ) ,Dr AP Dubey ( Expert Panel ) ,Dr Srujna Joga ( Expert Panel )

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

In this webinar, a detailed discussion is done on CROWN trial update: Optimizing 1st-line ALK+ mNSCLC management.

Speakers : Dr Srujna Joga ( Expert Panel ) ,Dr AP Dubey ( Expert Panel ) ,Dr Atul Sharma ( Expert Panel ) ,Dr Jyoti Wadhwa ( Moderator )

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

In this webinar, a detailed discussion is done on CROWN trial update: Optimizing 1st-line ALK+ mNSCLC management.

Speakers : Dr Srujna Joga ( Expert Panel ) ,Dr AP Dubey ( Expert Panel ) ,Dr Atul Sharma ( Expert Panel ) ,Dr Jyoti Wadhwa ( Moderator )

Efficient Management of First line ALK-rearranged NSCLC

In this webinar, a detailed discussion is done on the efficient management of first line ALK rearranged NSCLC.

Speakers : Dr B K ,Dr Abhishek Kakroo ,Dr Jogamaya Pattnaik

Efficient Management of First line ALK-rearranged NSCLC - Part V

Explore optimal first-line strategies for ALK-rearranged NSCLC to enhance survival and manage resistance.

Speakers : Dr Jogamaya Pattnaik ,Dr Abhishek Kakroo ,Dr B K Smruti

Efficient Management of First line ALK-rearranged NSCLC - Part IV

Explore optimal first-line strategies and targeted therapies for managing ALK-rearranged non-small cell lung cancer.

Speakers : Dr Jogamaya Pattnaik ,Dr Abhishek Kakroo ,Dr B K Smruti

Efficient Management of First line ALK-rearranged NSCLC - Part III

Explore optimal first-line strategies for managing ALK-rearranged NSCLC with advanced targeted therapies and clinical insights.

Speakers : Dr Jogamaya Pattnaik ,Dr Abhishek Kakroo ,Dr B K Smruti

Efficient Management of First line ALK-rearranged NSCLC - Part II

Discover effective first-line strategies for managing ALK-rearranged NSCLC using targeted therapies and personalized treatment approaches.

Speakers : Dr Jogamaya Pattnaik ,Dr Abhishek Kakroo ,Dr B K Smruti

Efficient Management of First line ALK-rearranged NSCLC - Part VI

In this webinar, a detailed discussion is done on the efficient management of first line ALK rearranged NSCLC.

Speakers : Dr Jogamaya Pattnaik

Efficient Management of First line ALK-rearranged NSCLC - Part VII

Explore first-line management strategies and targeted therapies for ALK-rearranged NSCLC to optimize patient outcomes.

Speakers : Dr Jogamaya Pattnaik ,Dr Abhishek Kakroo ,Dr B K Smruti


Recommended News For You

Cardiorespiratory fitness lowers the risk of colon, lung, and prostate cancer in MEN and lowers mortality from these diseases.

Scientists develop scans that light up aggressive cancer tumors for better treatment

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma

Older Adults With Advanced Cancer Prioritize Quality of Life

Researchers discuss HER2-low and HER2-zero in breast cancer

New protocols, according to a study, allow many patients to safely return home one day after lung cancer surgery.

Three out of ten breast cancers detected between screenings, study finds

Recommended Articles For You

The Pros and Cons of Steroid Therapy for ITP 

AI in the War on Cancer: How Digital Tools are Revolutionizing Oncology 

Survival Rate Dynamics in Hematologic and Solid Malignancies 

Understanding Blood Dyscrasia: Symptoms, Causes and Treatment Options 
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Beyond What Is Visible in Myelofibrosis?

2.

FDA approves rivanetin as the first-line treatment for lung cancer.

3.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

4.

New First-Line Option for Advanced ALK-Positive Lung Cancer

5.

Certain surgical gestures during prostate removal linked to better sexual function recovery

1.

Tremelimumab: A Potential Breakthrough in Cancer Treatment

2.

The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy

3.

Artificial Intelligence for Early Cancer Detection Leveraging Multi-Omics: A Comprehensive Review

4.

Harnessing Snake Venom in Hematology: From Toxins to Life-Saving Therapeutics

5.

Unlocking the Potential of SCD: A Comprehensive Guide to Diagnosis and Treatment

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII

2.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion

3.

Updates on Standard V/S High Risk Myeloma Treatment

4.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V

5.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot